Clinical Trial Update: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of IBI3003 for relapsed or refractory multiple myeloma is currently recruiting, sponsored by Innovent Biologics (Suzhou) Co. Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• IBI3003

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING